A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment

Muhammad Wasif Saif, Carlos R. Becerra, Marwan G. Fakih, Weijing Sun, Lazar Popovic, Smitha Krishnamurthi, Thomas J. George, Michelle A. Rudek, Dale R. Shepard, Jiri Skopek, Vladimir Sramek, Bojan Zaric, Ikuo Yamamiya, Karim A. Benhadji, Kensuke Hamada, Yaohua He, Lee Rosen

Open source

DOI: 10.1007/s00280-021-04308-z
Published: 2021-06-07
Container: Cancer Chemotherapy and Pharmacology
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s00280-021-04308-z,
  title = {A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment},
  author = {Muhammad Wasif Saif and Carlos R. Becerra and Marwan G. Fakih and Weijing Sun and Lazar Popovic and Smitha Krishnamurthi and Thomas J. George and Michelle A. Rudek and Dale R. Shepard and Jiri Skopek and Vladimir Sramek and Bojan Zaric and Ikuo Yamamiya and Karim A. Benhadji and Kensuke Hamada and Yaohua He and Lee Rosen},
  year = {2021},
  journal = {Cancer Chemotherapy and Pharmacology},
  doi = {10.1007/s00280-021-04308-z},
  url = {https://doi.org/10.1007/s00280-021-04308-z}
}

RIS

TY  - JOUR
TI  - A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment
AU  - Muhammad Wasif Saif
AU  - Carlos R. Becerra
AU  - Marwan G. Fakih
AU  - Weijing Sun
AU  - Lazar Popovic
AU  - Smitha Krishnamurthi
AU  - Thomas J. George
AU  - Michelle A. Rudek
AU  - Dale R. Shepard
AU  - Jiri Skopek
AU  - Vladimir Sramek
AU  - Bojan Zaric
AU  - Ikuo Yamamiya
AU  - Karim A. Benhadji
AU  - Kensuke Hamada
AU  - Yaohua He
AU  - Lee Rosen
PY  - 2021
JO  - Cancer Chemotherapy and Pharmacology
DO  - 10.1007/s00280-021-04308-z
UR  - https://doi.org/10.1007/s00280-021-04308-z
ER  -

APA

Saif, M. W., Becerra, C. R., Fakih, M. G., Sun, W., Popovic, L., Krishnamurthi, S., George, T. J., Rudek, M. A., Shepard, D. R., Skopek, J., Sramek, V., Zaric, B., Yamamiya, I., Benhadji, K. A., Hamada, K., He, Y., & Rosen, L. (2021). A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-021-04308-z

Source records

crossref · retrieved 2026-09-26T21:21:14.011Z